We see the pushback of donanemab’s sped up approval submission as only a velocity bump.
Cramer’s Making an investment Membership: Purchase Eli Lilly’s drop on drug extend information as it may not topic longer term
Your Global Perspective
Your Global Perspective
We see the pushback of donanemab’s sped up approval submission as only a velocity bump.
